× Key messages Background Findings Perspectives Expert commentary
Go back | list
format_size dark_mode
icon-previous icon-next

OnabotulinumtoxinA in combination with CGRP mAbs

Key messages

  • Data on the efficacy and safety of onabotulinumtoxinA in combination with calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAb) treatment in patients with chronic migraine is currently limited.
  • The addition of a CGRP mAb medication to patients undergoing onabotulinumtoxinA treatment for chronic migraine results in a significant reduction in monthly headache days and pain severity.